J G Te Marvelde
Overview
Explore the profile of J G Te Marvelde including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
716
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lhermitte L, Mejstrikova E, van der Sluijs-Gelling A, Grigore G, Sedek L, Bras A, et al.
Leukemia
. 2017 Nov;
32(4):874-881.
PMID: 29089646
Precise classification of acute leukemia (AL) is crucial for adequate treatment. EuroFlow has previously designed an AL orientation tube (ALOT) to guide towards the relevant classification panel (T-cell acute lymphoblastic...
2.
Feller N, van der Velden V, Brooimans R, Boeckx N, Preijers F, Kelder A, et al.
Blood Cancer J
. 2013 Aug;
3:e129.
PMID: 23912609
Flow-cytometric detection of minimal residual disease (MRD) has proven in several single-institute studies to have an independent prognostic impact. We studied whether this relatively complex approach could be performed in...
3.
Aalbers A, van den Heuvel-Eibrink M, de Haas V, Te Marvelde J, de Jong A, van der Burg M, et al.
Leukemia
. 2013 Mar;
27(9):1923-5.
PMID: 23493026
No abstract available.
4.
Kalina T, Flores-Montero J, van der Velden V, Martin-Ayuso M, Bottcher S, Ritgen M, et al.
Leukemia
. 2012 Sep;
26(9):1986-2010.
PMID: 22948490
The EU-supported EuroFlow Consortium aimed at innovation and standardization of immunophenotyping for diagnosis and classification of hematological malignancies by introducing 8-color flow cytometry with fully standardized laboratory procedures and antibody...
5.
Westers T, Ireland R, Kern W, Alhan C, Balleisen J, Bettelheim P, et al.
Leukemia
. 2012 Feb;
26(7):1730-41.
PMID: 22307178
Flow cytometry (FC) is increasingly recognized as an important tool in the diagnosis and prognosis of myelodysplastic syndromes (MDS). However, validation of current assays and agreement upon the techniques are...
6.
van der Velden V, van der Sluijs-Geling A, Gibson B, Te Marvelde J, Hoogeveen P, Hop W, et al.
Leukemia
. 2010 Jul;
24(9):1599-606.
PMID: 20668473
Analysis of minimal residual disease (MRD) in childhood acute myeloid leukemia (AML) may predict for clinical outcome. MRD levels were assessed by flowcytometric immunophenotyping in 94 children with AML enrolled...
7.
van Lochem E, van der Velden V, Wind H, Te Marvelde J, Westerdaal N, van Dongen J
Cytometry B Clin Cytom
. 2004 Jun;
60(1):1-13.
PMID: 15221864
Background: The abundance of monoclonal antibodies (mAb) and the routine use of quadruple stainings in flow cytometry allow stepwise analysis of bone marrow (BM) samples that are suspected for abnormal...
8.
van der Velden V, Boeckx N, Jedema I, Te Marvelde J, Hoogeveen P, Boogaerts M, et al.
Leukemia
. 2004 Mar;
18(5):983-8.
PMID: 15029214
Gemtuzumab ozogamicin (Mylotarg) induces remission in approximately 30% of relapsed AML patients. We previously demonstrated that gemtuzumab infusion results in near-complete CD33 saturation in peripheral blood, and that saturating gemtuzumab...
9.
van der Velden V, Te Marvelde J, Hoogeveen P, Bernstein I, Houtsmuller A, Berger M, et al.
Blood
. 2001 May;
97(10):3197-204.
PMID: 11342449
Antibody-targeted chemotherapy is a promising therapy in patients with acute myeloid leukemia (AML). In a phase II study of Mylotarg (CMA-676, gemtuzumab ozogamicin), which consists of a CD33 antibody linked...
10.
Levering W, van Den Beemd R, Te Marvelde J, van Beers W, Hooijkaas H, Sintnicolaas K, et al.
Cytometry
. 2000 May;
42(2):95-105.
PMID: 10797446
A biannual external quality assurance (EQA) scheme for flow cytometric typing of the HLA-B27 antigen is operational in The Netherlands and Belgium since 1995. We report here on the results...